
Maraviroc
CAS No. 376348-65-1
Maraviroc( Celsentri | Selzentry | UK 427857 )
Catalog No. M14297 CAS No. 376348-65-1
Maraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 42 | In Stock |
![]() ![]() |
10MG | 78 | In Stock |
![]() ![]() |
25MG | 147 | In Stock |
![]() ![]() |
50MG | 258 | In Stock |
![]() ![]() |
100MG | 465 | In Stock |
![]() ![]() |
200MG | 600 | In Stock |
![]() ![]() |
500MG | 945 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameMaraviroc
-
NoteResearch use only, not for human use.
-
Brief DescriptionMaraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively.
-
DescriptionMaraviroc is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively.(In Vitro):Maraviroc (UK-427857) is a selective CCR5 antagonist with potent anti-human immunodeficiency virus type 1 (HIV-1) activity. Maraviroc inhibits the downstream event of chemokine-induced intracellular calcium redistribution, with IC50s ranging from 7 to 30 nM obtained against MIP-1β, MIP-1α and RANTES.Maraviroc (UK-427857) is active (IC90) at low nanomolar concentrations against HIV-1 Ba-L (a lab-adapted R5 strain) when measured in a 5-day antiviral assay using either isolated multiple (pooled) donor PBMC (IC90, 3.1 nM), single-donor PBMC (IC90, 1.8 nM) or PM-1 cells (IC90, 1.1 nM)(In Vivo):Clearance values are moderate to high in both rat and dog species following i.v. administration (74 and 21 mL/min/kg, respectively). Maraviroc also has a moderate volume of distribution in both species (4.3 to 6.5 liters/kg). The half-life values of maraviroc are 0.9 h in the rat and 2.3 h in the dog. Following oral administration (2 mg/kg) to the dog, the Cmax(256 ng/mL) occurs 1.5 h. post-dose, and the bioavailability is 40%. For the rat, investigation of the concentrations obtain in the portal vein following oral administration indicated that approximately 30% of the administered dose is absorbed from the intestinal tract. In the DSS/TNBS colitis and in the transfer model, Maraviroc attenuates development of intestinal inflammation by selectively reducing the recruitment of CCR5 bearing leukocytes.
-
In Vitro——
-
In Vivo——
-
SynonymsCelsentri | Selzentry | UK 427857
-
PathwayAutophagy
-
TargetCCR
-
RecptorMIP-1α| MIP-1β| RANTES
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number376348-65-1
-
Formula Weight513.67
-
Molecular FormulaC29H41F2N5O
-
Purity>98% (HPLC)
-
SolubilityEthanol: 100 mg/mL (194.67 mM); DMSO: 100 mg/mL (194.67 mM)
-
SMILESCC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C
-
Chemical Name4,4-difluoro-N-[(1S)-3-[(1S,5R)-3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Dorr P, et al. Antimicrob Agents ChemOthers. 2005, 49(11), 4721-4732.
molnova catalog



related products
-
CCR8 antagonist 1
CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.
-
GSK2239633A
GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.
-
CCR6 antagonist 1
CCR6 antagonist 1, a chemical compound acting as a CCR6 antagonist, effectively inhibits the CCL20/CCR6 axis. Its utility lies in research focused on autoimmune-mediated inflammatory diseases, including inflammatory bowel diseases (IBDs).